Novartis brings Lutathera to adolescents with rare cancer in first for radioligand class
Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut.
The radioligand therapy won a label expansion on Tuesday for patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. Neuroendocrine tumors are exceedingly rare, with only a few thousand diagnoses per year in the US, according to MD Anderson.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
